Strong drug sales offset medical device slowdowns and generic pressure
- Q3 2026 showed a clear split between strong drug sales and weaker medical device results.
- Innovative Medicine grew nearly 8 percent led by new product launches like TREMFYA.
- MedTech growth slowed to 2.5 percent due to international issues and Abiomed weakness.
- The company proposed a 5.5 billion dollar settlement for ovarian talc lawsuits.
- A new surgical robot called OTTAVA won regulatory clearance to enter the market.
A patent cliff expands while device growth stalls
Johnson & Johnson is proving the main bull case for its drug business. STELARA is falling hard after cheaper copies entered the market, but the rest of the drug portfolio is growing fast enough to offset the damage. In Q3 2026, the Innovative Medicine segment grew almost 8 percent operationally. Oncology drugs and newer immunology treatments like TREMFYA are taking dominant market share.
However, the medical device business is now a worry. Abiomed was supposed to be a key growth engine in cardiovascular devices, but sales fell again in Q3. Doctors are using the product more carefully. The company also faced international device headwinds from pricing changes in China and delayed orders in the Middle East. MedTech growth fell well short of internal targets.
Finn's view is balanced. JNJ has real growth engines in pharmaceuticals and a new surgical robot named OTTAVA that just won clearance. It also proposed a massive 5.5 billion dollar settlement to finally resolve its talc litigation overhang. But with medical devices struggling and generic drug competition expanding, the stock still has to earn its price.
Patents, hospitals, and surgical suites
Johnson & Johnson makes money in two main ways. Innovative Medicine sells patented prescription drugs. MedTech sells devices used by surgeons, heart doctors, eye doctors, and hospitals.
The drug business is highly profitable while a product has patent protection. The risk is that sales fall fast when cheaper copies arrive, as STELARA, SIMPONI, and OPSUMIT show. That is why JNJ needs new launches like TREMFYA and ICOTYDE to keep replacing older products.
The device business depends on hospital budgets, doctor training, and procedure volumes. A single clinical study can change behavior quickly. Abiomed's recent struggles show that MedTech is exposed to sudden shifts in doctor confidence.
JNJ benefits from massive research spending, global sales reach, and long relationships with healthcare providers. Those strengths are real, but they do not remove legal risk, pricing pressure, or product cycle risk.
The products that drive the future
DARZALEX
DARZALEX is the largest product for JNJ and treats multiple myeloma, a blood cancer. It drives significant growth for the company.
STELARA, SIMPONI, and OPSUMIT
These legacy drugs were major profit pools but now face cheaper generic or biosimilar competition, driving steep sales declines.
TREMFYA
TREMFYA is now the main immunology growth story. It recently took the top share for new prescriptions in key bowel disease markets.
Abiomed
This cardiovascular device franchise is under pressure after a neutral trial caused doctors to change their usage habits.
OTTAVA
This new robotic surgical system just won regulatory clearance, giving JNJ a path into a highly profitable surgical market.
Orthopaedics
Orthopaedics sells joint implants and related surgical products. JNJ plans to spin this business off to sharpen its growth focus.
Two businesses, one bigger drug engine
Segment mix uses Q3 2026 sales. Innovative Medicine generated 16.8 billion dollars and MedTech generated 8.6 billion dollars.
What could break the thesis
Generics fall faster than replacements grow
High impact · High oddsSTELARA biosimilars are already hurting sales, and SIMPONI and OPSUMIT just lost exclusivity. The key question is whether oncology and new immunology drugs can keep offsetting multiple declining legacy products.
Abiomed weakness becomes structural
High impact · Medium oddsAbiomed sales fell 1.5 percent in Q3 2026 after doctors reacted to a neutral UK trial. Management called the effect behavioral, but doctor behavior can stick. If growth does not recover before the PROTECT IV readout in 2027, a key MedTech growth pillar may be stalled.
Talc settlement fails to reach the threshold
High impact · Medium oddsJNJ proposed a 5.5 billion dollar resolution for ovarian talc claims. However, this agreement requires 95 percent of claimants to opt in. If that threshold is missed, the litigation overhang remains active and costly.
International device markets stall
Medium impact · High oddsThe MedTech business faces international headwinds like volume-based pricing in China and tender delays in the Middle East. If these issues are structural rather than temporary, device growth will struggle.
Orthopaedics separation disappoints
Medium impact · Medium oddsJNJ plans to separate Orthopaedics via a spin-off. The move could sharpen the remaining company's growth profile, but it also brings execution risk. Investors still need details on debt, margins, and the growth profile of the separated company.
In one breath
What does Johnson & Johnson do now?
After separating consumer health, JNJ is mainly a prescription drug and medical device company. Its two segments are Innovative Medicine and MedTech.
Why are STELARA, SIMPONI, and OPSUMIT losing sales?
These drugs face biosimilar or generic competition, which means cheaper versions can take share. JNJ must replace that lost sales base with newer drugs.
Why does Abiomed matter?
Abiomed is a major part of JNJ's cardiovascular device growth plan. Its recent sales declines raised questions about whether doctor caution is temporary or lasting.
Is Johnson & Johnson cheap?
Finn's valuation score is below the middle of the range, so the price is not an obvious bargain. The company has quality assets, but investors still need proof that growth can keep compounding.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- October 18, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Johnson & Johnson in Finn's Drug Manufacturers - General industry ranking.

